Skip to content
Colorectal Cancer Clinical Trials

Omaha, Nebraska

Colorectal cancer clinical trials in Omaha, NE

27 colorectal cancer studies are recruiting participants at sites in Omaha as of November 16, 2026, according to ClinicalTrials.gov. Colorectal Cancer Clinical Trials can help you understand your options and connect with a study team.

Call (888) 385-9581
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Omaha at a glance

  • 27 studies are recruiting at a site in Omaha.
  • By phase: Phase 1 (4), Phase 1/2 (4), Phase 2 (4), Phase 2/3 (2), Phase 3 (6), No phase (3), Observational (4). Studies of devices and behavioral approaches have no phase.
  • By sponsor: industry (18), university, hospital or other (9).
  • Most recent update to one of these records: November 12, 2026.

Studies recruiting in Omaha

Basic details from each study's public record. Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    University Of Nebraska Medical Center ( Site 0078)
    Registry record
    NCT06997497 · updated
  2. Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study sites
    Oncology Hematology West, PC dba Nebraska Cancer Specialists - Bergan · Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy · Oncology Hematology West, PC dba Nebraska Cancer Specialists - Methodist
    Registry record
    NCT07750158 · updated
  3. Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Alegent Health Bergan Mercy Medical Center · Alegent Health Immanuel Medical Center · Alegent Health Lakeside Hospital
    Registry record
    NCT07018869 · updated
  4. Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps

    • No phase
    • Ages 45 to 70
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Alegent Health Bergan Mercy Medical Center · Alegent Health Immanuel Medical Center · Alegent Health Lakeside Hospital
    Registry record
    NCT05080673 · updated
  5. Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    NRG Oncology
    Study sites
    Alegent Health Bergan Mercy Medical Center · Alegent Health Immanuel Medical Center · Alegent Health Lakeside Hospital
    Registry record
    NCT05174169 · updated
  6. Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

    • Observational
    • Ages 40 to 75
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Alegent Health Bergan Mercy Medical Center · Alegent Health Immanuel Medical Center · Alegent Health Lakeside Hospital
    Registry record
    NCT05334069 · updated
  7. Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Alegent Health Bergan Mercy Medical Center · Alegent Health Immanuel Medical Center · Alegent Health Lakeside Hospital
    Registry record
    NCT07283939 · updated
  8. Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Nebraska Medicine-Village Pointe · University of Nebraska Medical Center
    Registry record
    NCT05673148 · updated
  9. A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Nebraska Cancer Specialists Midwest Cancer Center
    Registry record
    NCT06662786 · updated
  10. A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Janssen Research & Development, LLC
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT06750094 · updated
  11. Family Communications After Genetic Testing

    • No phase
    • Ages 18 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study sites
    Alegent Health Bergan Mercy Medical Center · Alegent Health Immanuel Medical Center · Alegent Health Lakeside Hospital
    Registry record
    NCT07143487 · updated
  12. A Study to Investigate CEA-PRIT 2.0 in Participants With Metastatic Colorectal Cancer (mCRC)

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT07416552 · updated
  13. Lead-212 PSV359 Therapy for Patients With Solid Tumors

    • Phase 1/2
    • Ages 18 to 90
    • All sexes
    Sponsor
    Perspective Therapeutics
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT06710756 · updated
  14. A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646
    Registry record
    NCT06820463 · updated
  15. A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

    • Phase 2/3
    • Ages 18 and older
    • All sexes
    Sponsor
    Bristol-Myers Squibb
    Study site
    University Of Nebraska Medical Center
    Registry record
    NCT07221357 · updated
  16. Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    University of Nebraska
    Study site
    University of Nebraska Medical Center
    Registry record
    NCT05254327 · updated
  17. Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Exelixis
    Study site
    Exelixis Clinical Site #2
    Registry record
    NCT05176483 · updated
  18. 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Radiopharm Theranostics, Ltd
    Study sites
    Nebraska Cancer Specialists · XCancer
    Registry record
    NCT07189871 · updated
  19. Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study sites
    Nebraska Cancer Specialists · University of Nebraska Medical Center
    Registry record
    NCT06445062 · updated
  20. Safely Optimizing Body Weight With Mifomelatide (TCMCB07) in Patients With Newly Diagnosed Colorectal Cancer (CRC) or Pancreatic Ductal Adenocarcinoma (PDAC) Undergoing Chemotherapy

    • Phase 2
    • Ages 18 and older
    • All sexes
    Sponsor
    Endevica Bio
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT06937177 · updated
  21. Integrated Cancer Repository for Cancer Research

    • Observational
    • Ages 19 to 110
    • All sexes
    Sponsor
    University of Nebraska
    Study sites
    Methodist Estabrook Cancer Center · Nebraska Methodist Health System · University of Nebraska Medical Center
    Registry record
    NCT02012699 · updated
  22. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    AbbVie
    Study site
    Nebraska Cancer Specialists - Omaha - Wright Street /ID# 247399
    Registry record
    NCT05005403 · updated
  23. Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Orano Med Theranostics, SAS
    Study sites
    Nebraska Cancer Specialists (Midwest Cancer Center - Legacy) · XCancer Omaha / Urology Cancer Center
    Registry record
    NCT05283330 · updated
  24. Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Tasca Therapeutics
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT07030257 · updated
  25. Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    GlaxoSmithKline
    Study site
    GSK Investigational Site
    Registry record
    NCT05855200 · updated
  26. SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

    • Observational
    • All ages
    • All sexes
    Sponsor
    Massive Bio, Inc.
    Study site
    Massive Bio SYNERGY-AI site
    Registry record
    NCT03452774 · updated
  27. Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays

    • Observational
    • Ages 18 and older
    • All sexes
    Sponsor
    Tempus AI
    Study site
    Nebraska Cancer Specialists
    Registry record
    NCT05234177 · updated

Source: ClinicalTrials.gov. Data processed . See every colorectal cancer study recruiting in Omaha, NE on ClinicalTrials.gov.

Ask about studies near Omaha

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 16, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded.

Colorectal Cancer Clinical Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 385-9581

or send a short form

How should we reach you?

Call